SMMT - Why Summit Therapeutics Stock Is Trading 8% Higher Monday | Benzinga
Summit Therapeutics, Inc. (NASDAQ:SMMT) stock is moving higher Monday following the company’s announcement that it received marketing authorization in China for ivonescimab in combination with chemotherapy.
What Happened: Based on data from a Phase III HARMONi-A clinical trial, sponsored by Akeso, that showed promising results for treating certain cancers, China granted Summit the marketing authorization.
Specifically, the clinical trial included patients with certain types of advanced non-small cell lung cancer. The overall response rate for the combined treatment was ...